EINPRESSWIRE

Labiana posts revenues of over €39 million in the first half of 2025, up 11.7% year-on-year

Labiana posts strong H1 2025 results with €7.4M adjusted EBITDA, up 12.8%, driven by growth in animal and human health divisions.



Labiana Health H1 2025 highlights: solid revenue growth, higher profitability, and balanced performance across animal and human health divisions.

MADRID, MADRID, SPAIN, October 31, 2025 /EINPresswire.com/ -- Labiana, the Spanish pharmaceutical group dedicated to the development, manufacture, and marketing of medicines in the areas of animal and human health and listed on BME Growth, reported revenues of €39.2 million in the first half of 2025, up 11.7% compared to the same period in 2024. This growth was mainly driven by the acceleration of the animal health business, both in the Spanish and European markets.

Gross margin on sales reached 60.2% and likewise, gross margin rose 7.2% compared to the first half of 2024. In addition, the Group further increased its net profit by 54.8% to €1.82 million, demonstrating a clear improvement in the Group's operating profitability, directly reflected in its bottom line.

Adjusted EBITDA closed at €7.44 million, up 12.8%, while adjusted EBIT also increased, reaching €5.42 million, also showing strong double-digit growth of 29.2%.

By business segment, both the animal health and human health recorded positive growth in the first half of the year. Specifically, animal health generated revenues of €18.9 million, an 18.8% increase, supported by new CDMO (Contract Development and Manufacturing Organization) clients and higher demand for its own products, driven by increased consumption of injectables in the Spanish market—a segment in which Labiana is the leading manufacturer in Spain and among the top in Europe.

The human health division maintained a solid pace of sustainable growth, achieving a year-on-year increase of 4.7% with revenues of €20.3 million. During this period, it also invested in strengthening the production capacity of this business line, which will increase its industrial capabilities and improve operational efficiency in the short term.

In terms of geographical areas, Labiana continues to expand its presence across all export markets (EU excluding Spain, North America, and the rest of the world). The Spanish market also posted significant growth in the animal health segment, reflecting the consolidation of the Company's portfolio and the success of recently launched developments.

According to Manuel Ramos, CEO of Labiana, "Labiana maintains a positive and profitable growth path, fully aligned with the objectives of our business plan, achieving improvements in all key metrics while maintaining a healthy balance between sales growth, profitability, and cost control."

Results webcast
A webcast presentation of the results will take place on Monday, November 3, at 10:00 a.m. (CET). The online session will highlight the main developments in each business segment and review the Company's financial performance. Participation will be open, subject to prior registration, through the following link.

About Labiana
Labiana Health is a leading independent and fully integrated international Company operating in the animal and human health industries. It has a diversified portfolio of products and business lines and a broad base of top-tier clients with long-standing relationships built on trust.

The Group's products are currently available in more than 150 markets, with its own products registered in over 114 countries. This global presence is supported by two GMP (Good Manufacturing Practice) manufacturing plants in Spain, international subsidiaries in Turkey, Ecuador, and Mexico, a stake in Serbia, a growing network of multinational clients, and licensing agreements with international distributors for the commercialization of its proprietary products.

The Group operates two distinct yet complementary business lines: contract manufacturing, which provides stability and revenue visibility; and product development, manufacturing, and marketing, which drive growth. The Company made its debut on the BME Growth market in June 2022, becoming the first veterinary Company to be listed on that exchange.

Cristina Ramos
LABIANA HEALTH, S.A.

34 93 736 97 00
email us here
Visit us on social media:
LinkedIn
